GlassScriptPhysician profile
Mitchell R Grunsky
NPI 1124105010
$7,121.07
in general payments reported to CMS, 2019-2025
46 companies · $850 in 2025
The $850 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $1,064 · 2021: $1,815 · 2022: $1,335 · 2023: $423 · 2024: $882 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $703.14 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $520.23 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $507.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $487.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $352.57 | 2021-2023 | Xarelto |
| Pfizer INC. | $280.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.76 | 2019-2025 | Jardiance, Synjardy |
| Teva Pharmaceuticals USA, INC. | $231.74 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.99 | 2019-2023 | Trintellix |
| Amgen INC. | $194.73 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Esperion Therapeutics, INC. | $186.61 | 2020-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $182.96 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $176.25 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.74 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Grunsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.